California Gov. Gavin Newsom has angered his left-wing base with an action taken late last week.
Newsom vetoed legislation that would have strengthened California’s status as a legal sanctuary for abortion providers and providers of gender-related medical care, breaking with progressive groups that wanted the protections written permanently into state law.
Newsom rejected Assembly Bill 2164, legislation that would have prohibited California governors from extraditing people accused by other states of crimes involving reproductive or gender-related health care that is legal in California.
The Democratic governor said his objection centered on preserving the constitutional authority of the governor rather than disagreement with California’s broader protections for abortion and transgender medical care.
Newsom’s decision nevertheless surprised abortion-rights organizations because the legislation was designed largely to codify a policy he established himself through executive order in 2022.
That policy instructs California officials to decline certain extradition requests involving reproductive health care that is legal in California.
The issue has moved from theoretical legal debate to an actual interstate confrontation.
Earlier this year, Louisiana sought the extradition of a California physician accused of prescribing abortion medication through telehealth to a Louisiana patient.
Newsom rejected the request in January.
“Louisiana’s request is denied,” Newsom said at the time. “My position on this has been clear since 2022: We will not allow extremist politicians from other states to reach into California and try to punish doctors based on allegations that they provided reproductive health care services.”
AB 2164 would have taken that policy largely out of the hands of future governors by putting the protections into state law.
The veto means California’s current protections remain in place while Newsom is governor, but his successor could potentially take a different approach to extradition requests.
That possibility has alarmed abortion-rights organizations.
Pavitra Abraham, state campaigns director for Reproductive Freedom for All, warned that abortion providers remain “just one election away from extradition.”
Supporters of the bill argue providers should not have to depend on the political views of whoever occupies the governor’s office.
Opponents of AB 2164 welcomed Newsom’s decision for a different reason.
Several organizations opposed to gender-related medical interventions for minors argued the legislation could have protected California doctors from legal accountability when patients lived in states restricting such treatments.
The legislation covered both “reproductive health care services” and “gender affirming health care services.”
Critics also raised constitutional questions involving the Full Faith and Credit Clause and states’ obligations to recognize certain legal proceedings originating elsewhere.
Newsom’s veto does not represent a broader reversal of California’s abortion policies.
California has enacted an extensive network of shield laws since the Supreme Court overturned Roe v. Wade in 2022.
Those laws restrict cooperation with investigations and legal proceedings initiated by states attempting to punish abortion providers for conduct lawful in California. Newsom strengthened those protections again in 2025.
Among other measures, he signed AB 260, which expanded protections for providers prescribing abortion medication and allowed doctors in certain circumstances to prescribe the drugs without placing their names on prescription labels.
California’s shield laws have become increasingly important because abortion medication can cross state lines without either the doctor or patient traveling.
Doctors practicing in states such as California and New York can prescribe mifepristone through telehealth and mail the medication to patients living in states where abortion is heavily restricted.
New York’s shield law explicitly protects providers physically located in New York who provide reproductive health care through telehealth to patients outside the state.
That practice has produced an emerging constitutional confrontation between states.
Louisiana’s ongoing challenge to the Food and Drug Administration’s rules governing mifepristone illustrates the stakes.
Louisiana and other challengers are seeking tighter federal restrictions on the abortion drug, arguing that the FDA improperly loosened safeguards that previously required greater in-person medical supervision.
A three-judge panel of the 5th U.S. Circuit Court of Appeals recently heard arguments in the case.
The current FDA rules permit mifepristone to be prescribed through telehealth and delivered by mail, making it considerably easier for providers in shield-law states to prescribe the medication to patients elsewhere.
Louisiana argues that those federal rules interfere with its ability to enforce its own abortion laws.
This article may contain commentary which reflects the author's opinion.
